IP Library Granted Patent US 7,335,381
Granted Patent B2
US 7,335,381 · App. 10/956,487 · Granted Feb 26, 2008

Transplantable particulate bone composition having high osteoinductive capacity and methods for making and using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,335,381
App. No.
10/956,487
Granted
Feb 26, 2008
Kind
B2
Abstract

A particulate bone of defined sizes which has a unique property of direct bone osteoinduction without going through endochondral ossification stage is disclosed. The bone is not subjected to chemical extraction or decalcification. This allows for the retention of all physiologically active components of native bone. The invention hinges on the newly discovered ability of bone particles of defined sizes to exert osteoinduction by a pathway superior to and distinct from demineralized bone matrix and similar preparations.

Claims (58)

1. A composition for use as a bone implant comprising particulate bone including particles having sizes less than or equal to about 355 μm and having a particle size distribution including from about 24.6 wt % to about 36.3 wt % of particles having a particle size between about 350 μm and about 250 μm, from about 22 wt % to about 25 wt % of particles having a particle size between 250 μm and about 150 μm, and from about 36.7 wt % to about 46.7 wt % of particles having a particle size less than 150 μm, and prepared from bone having an initial temperature between about 18° C. and about 20° C. and ground in a mill under conditions so that the bone is not heated above a critical temperature of less than or equal to 40° C., where the particulate bone is non-chemically extracted, non-demineralized, and where said composition has improved osteoinductive activity and regeneration of bone defects as compared to demineralized particulate bone.

2. The composition of claim 1 , further comprising a particle size distribution of particles having sizes between about 25 μm and about 355 μm.

3. The composition of claim 2 , wherein the particle size distribution includes about 50 wt % of particles having a particle size between about 250 μm and about 150 μm, about 25 wt % of paticles having a particles size between about 150 μm and about 100 μm, and about 25 wt % of particles having a particle size less than about 100 μm.

4. The composition of claim 1 , wherein the particulate bone is particulate cortical bone, particulate cancellous bone or mixtures or combinations thereof.

5. The composition of claim 1 , wherein the bone is selected from the group consisting of autograft bone, allograft bone, xenograft bone and mixtures or combinations thereof.

6. The composition of claim 1 , wherein the particles having a particle size below about 250 μm, comprise:

from about 35 wt % to 65 wt % of particles having a particle size between about 250 μm and about 150 μm,

from about 10 wt % to about 40 wt % of particles having a particles size between about 150 μm, and about 100 μm, and

from about 10 wt % to about 40 wt % of particles having a particle size less than about 100 μm.

7. The composition of claim 1 , wherein the particles having a particle size below about 250 μm comprise:

from about 40 wt % to about 60 wt % of particles having a particle size between about 250 μm and about 150 μm,

from about 15 wt % to about 35 wt % of particles having a particles size between about 150 μm and about 100 μm, and

from about 15 wt % to about 35 wt % of particles having a particle size less than about 100 μm.

8. The composition of claim 1 , wherein the particles having a particle size below about 250 μm comprise:

about 50 wt % of particles having a particle size between about 250 μm and about 150 μm,

about 25 wt % of particles having a particles size between about 150 μm and about 100 μm, and

about 25 wt % of particles having a particle size less than about 100 μm.

9. A method for making a particulate bone composition according the claim 1 , comprising the step of grinding non-chemically extracted and non-demineralized bone having an initial temperature between about 18° C. and about 20° C. in a mill, while maintaining the bone at a temperature at or below a critical temperature of less than or equal to 40° C. to produce the praticulate bone composition comprising particles having sizes less than or equal to about 355μm, where the temperature reduces damage to the bone, and where the particulate bone composition has improved osteoinductive activity and regeneration of bone defects as compared to demineralized particulate bone.

10. The method of claims 9 , wherein the critical temperature is 40° C.

11. The method of claim 9 , wherein the critical temperature is 35° C.

12. The method of claim 9 , wherein the critical temperature is 33° C.

13. The method of claim 9 , wherein the bone, prior to commutating, is selected from the group consisting of dry bone, wet bone, freeze-dried bone, frozen nascent bone, and mixtures or combinations thereof.

14. The method of claim 9 , wherein the bone is selected from the group consisting of autografe bone, allograft bone, xenograft bone and mixtures or combinations thereof.

15. A method for making a particulate bone composition according the claim 1 , comprising the step of grinding non-chemically extracted and non-demineralized bone having an initial temperature between about 18° C. and about 20° C. for a first period of time to form crude particulate bone composition in a mill; sieving the crude particulate bone composition for a second period of time to form sieved particulate bone composition; and repeating the grinding and sieving steps for a third period of time sufficient to produce the particulate bone composition comprising particles having sizes less than or equal to about 355 μm, where the grinding and sieving steps are performed so that a temperature to which the bone is exposed is maintained below a critical temperature of less than or equal to 40° C. to reduce or eliminate loss of osteoinductive activity, and where the particulate bone composition has improved osteoinductive activity and regeneration of bone defects as compared to demineralized particulate bone.

16. The method of claim 15 , wherein the first period of time is between about 8 seconds and about 18 seconds.

17. The method of claim 15 , wherein the second period of time is between about 14 seconds and about 15 seconds or longer.

18. The method of claim 15 , wherein the third period of time is about 3 minutes.

19. The method of claim 15 , wherein the third period of time is about 2.5 minutes.

20. The method of claims 15 , wherein the critical temperature is 40° C.

21. The method of claim 15 , wherein the critical temperature is 35° C.

22. The method of claim 15 , wherein the critical temperature is 33° C.

23. The method of claim 15 , wherein the bone, prior to commutating, is selected from the group consisting of dry bone, wet bone, freeze-dried bone, frozen nascent bone, and mixtures or combinations thereof.

24. The method of claim 15 , wherein the bone is selected from the group consisting of autograft bone, allograft bone, xenograft bone and mixtures or combinations thereof.

25. A method for treating bone defects comprising the step of implanting a therapeutically effective amounts of a particulate bone composition according to claim 1 , including non-chemically extracted and non-demineralized particulate bone into a bone defect of an animal including a human, where the composition has improved osteoinductive activity as compared to demineralized particulate bone, and where the composition induces healing of the bone defect via the implantation of said composition into said defect.

26. The method of claim 25 , wherein the composition induces significant healing of the defect six week post implantation.

27. The method of claim 25 , further comprising a particles size distribution of particles having sizes between about 25μ and about 335μ.

28. The method of claim 27 , wherein the distribution includes:

from about 24.6 wt % to about 36.3 wt % of particles having a particle size between about 350 μm and about 250 μm;

from about 22 wt % to about 25 wt % of particles having a particle size between 250 μm and about 150 μm; and

from about 36.7 wt % to about 46.7 wt % of particles having a particle size less than 150 μm.

29. The method of claim 28 , wherein the particles having a particle size below about 250μ comprise:

from about 35 wt % to 65 wt % of particles having a particle size between about 250 μm and about 150 μm,

from about 10 wt % to about 40 wt % of particles having a particles size between about 150 μm and about 100 μm; and

from about 10 wt % to about 40 wt % of particles having a particle size less than about 100 μm.

30. The method of claim 28 , wherein the particles having a particle size below about 250μ comprise:

from about 40 wt % to about 60 wt % of particles having a particle size between about 250 μm and about 150 μm,

from about 15 wt % to about 35 wt % of particles having a particle size between about 150 μm and about 100 μm, and

from about 15 wt % to about 35 wt % of particles having a particle size less than about 100 μm.

31. The method of claim 28 , wherein the particle having a particle size below about 250 μm comprise:

about 50 wt % of particles having a particle size between about 250 μm and about 150 μm,

about 25 wt % of particles having a particle size between about 150 μm and about 100 μm, and

from about 25 wt % of particles having aparticle size less than 100 μm.

32. The method of claim 27 , wherein the particle size distribution includes about 50 wt % of particles having a particle size between about 250 μm, and about 150 μm, about 25 wt % of particles having a particle size between about 150 μm and about 100 μm, and about 25 wt % of particles having a particle size less than about 100 μm.

33. The method of claim 25 , wherein the particulate bone is particulate cortical bone, particulate cancellous bone or mixtures or combinations thereof.

34. The method of claim 33 , wherein the bone is selected from the group consisting of autograft bone, allograft bone xenograft bone and mixtures or combinations thereof.

35. A composition comprising particulate bone having a particle size distribution comprising from about 24.6 wt % to about 36.3 wt % of particles having a particle size between about 350 μm and about 250 μm, from about 22 wt % to about 25 wt % of particles having a particle size betweeen 250 μm and about 150 μm, and from about 36.7 wt % to about 46.7 wt % of particles having a particle size less than 150 μm, where the particulate bone is non-chemically extracted and non-demineralized and prepared from bone having an initial temperature between about 18° C. and about 20° C. and groung in mill under conditions so that the bone is not heated above a critical temperature of less than or equal to 40° C., and where said composition has improved osteoinductive activity and regeneration of the bone defects as compared as compared to demineralized particulate bone.

36. The composition of claim 35 , wherein the particulate bone is particulate cortical bone, particulate cancellous bone or mixtures or combinations thereof.

37. The composition of claim 35 , wherein the bone is selected from the group consisting of autograft bone, xenograft bone and mixtures or combinations thereof.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Aug 29, 2022
From: BANKUNITED, N.A.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 061333/0853 →
SECURITY INTEREST Recorded Aug 4, 2022
From: VIVEX BIOLOGICS GROUP, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 061084/0607 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2019
From: HERITAGE BANK OF COMMERCE
To: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
Reel/Frame 051282/0653 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 11, 2019
From: VIVEX BIOLOGICS GROUP, INC.
To: BANKUNITED, N.A.
Reel/Frame 051260/0064 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOMEDICAL, INC.
To: VIVEX BIOLOGICS, INC.
Reel/Frame 050079/0179 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOLOGICS, INC.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 050079/0225 →
RELEASE OF SECURITY INTEREST Recorded Mar 28, 2017
From: SILICON VALLEY BANK
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 042103/0686 →
SECURITY INTEREST Recorded Feb 22, 2017
From: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC.; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 041782/0452 →
SECURITY INTEREST Recorded Jan 5, 2016
From: VIVEX BIOMEDICAL, INC.
To: SILICON VALLEY BANK
Reel/Frame 037413/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2013
From: LOSTEC, INC.
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 031194/0023 →